Golcadomide
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Golcadomide
- Molecular weight
- 535.58
- Structure (SMILES)
- O=C1CC[C@H](N2C(=O)c3cccc(NCc4ccc(CN5CC(N6CCOCC6)C5)cc4F)c3C2=O)C(=O)N1
- cc 99282
- Cc 99282
- CC-99282
- cc1007548
- CC1007548
- cc99282
- CC99282
- golcadomida
- Golcadomida
- golcadomide
- Golcadomide
- golcadomide [INN]
- GOLCADOMIDE [USAN]
- Golcadomide [WHO-DD]
- golcadomide inn
- golcadomide usan
- golcadomide who dd
- CAS registry numbers
- 2379572-34-4
- ChEMBL ID
- CHEMBL5095226
- InChIKey
- NZYDBVQXOGPDDU-QHCPKHFHSA-N
- PubChem compound IDs
- 146195299
- FDA ingredient codes (UNII)
- 29HLR8Z5BR
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- golcadomide
- Type
- Synthetic organic
- Drug name stem
- -domide
Mechanisms of action
- Action
- Binding
- Action type
- Binding
- Target
- cereblon
- Gene symbol
- CRBN
- Protein identifier
- Q96SW2
- Condition
- Lymphoma, Large B-Cell, Diffuse
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000403
- Subject identifier
- D016403
- Condition
- Lymphoma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000574
- Subject identifier
- D008223
- Condition
- Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Lymphoma, Non-Hodgkin
- Highest recorded phase
- 2
- Condition identifier
- EFO:0005952
- Subject identifier
- D008228
- Condition
- Lymphoma, Follicular
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0018906
- Subject identifier
- D008224
- Condition identifier
- EFO_0000616
- Highest recorded phase
- 2
- Condition identifier
- EFO_0005952
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0000430
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0004948
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005070
- Condition identifier
- MONDO_0015760
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0017604
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0018876
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0018905
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0018906
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0018908
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0044889
- Highest recorded phase
- 2
- NCT03310619
- NCT05788081
- NCT06108232
- NCT06425302
- NCT06356129
- NCT03930953
- NCT04434196
- NCT05169515
- NCT05283720
- NCT04884035
- Hydrogen bond acceptors
- 8
- Hydrogen bond donors
- 2
- Polar surface area
- 111.29
- Calculated partition coefficient (ALogP)
- 1.36
- Calculated partition coefficient (XLogP)
- 1.6
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 1
- Rotatable bonds
- 7
- Heavy atoms
- 39
- Molecular formula
- C28H30FN5O5
- Monoisotopic mass
- 535.22309724
- Natural product
- No
Related records
Trials (23)
- A Combination of Rituximab and CC-99282 as Front-line Therapy for Older Frail Patients With Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated With a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL)
- A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas
- A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies
- A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)
- A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
- A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
- A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
- A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
- A Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibitor (Itraconazole) and Inducer (Rifampin) on the Drug Levels of Golcadomide (BMS-986369) in Healthy Participants
- A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma
- A Study to Evaluate the Pharmacokinetics and Safety of Golcadomide in Participants With Severe Renal Impairment and End-Stage Renal Disease Compared With Participants With Normal Renal Function
- CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma
- Golcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With Refractory Disease After Chimeric Antigen T-cell Therapy
- Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy
- Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma
- Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse
- Golcadomide With Pemetrexed, Rituximab, and Dexamethasone for Relapsed and Refractory CNS Lymphomas
- Golcadomide, Poseltinib, and Rituximab for Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma
In development for (5)
- Diffuse large B-cell lymphoma Phase 3
- Follicular lymphoma Phase 2
- Lymphoma Phase 1
- Neoplasm Phase 2
- Non-Hodgkin lymphoma Phase 2